Macroeconomic Policy Impact On Oncology-Related Public Expenditure In An Emerging European Market – Signs Of Early Recovery

Abstract

SAŽETAK Cilj studije je analiza trendova u javnim izdvajanjima za onkolosku zdravstvenu zaštitu u godinama duboke ekonomske recesije u svetu i na Balkanu. Ostali ciljevi su utvrditi fi nu strukturu troškova u ovoj kliničkoj disciplini kao i eventualno prisustvo korelacije obima potrošnje na dijagnostiku i lečenje malignih neoplazmi sa makroekonomskim kretanjima i zdravstvenom politikom u Srbiji.Primenjena je retrospektivna studija slučaja, kojom je obuhvaćen period od cetiri godine (2010-2013.) €7, 411, 446 u 2010€7, 411, 446 u na €5, 715, 884 u 2012€7, 411, 446 u i iznova snažno skočili na €8, 536, 364 u 2013 €7, 411, 446 in 2010€7, 411, 446 in to €5, 715, 884 in 2012€7, 411, 446 in and then increased to an extraordinary €8, 536, 364 in 2013

Polypharmacy among the elderly in the Republic of Srpska: extent and implications for the future

“…100% patient co-payment. Careful monitoring of medicines consumption combined with ongoing reforms enables the reimbursement of expensive targeted pharmaceuticals and other high-budget-impact medicines(54)(55)(56).…”

An evaluation of the cost‐effectiveness of the different palliative care models available to cancer patients in Turkey

“…A total of 167,463 people was diagnosed with cancer and the cancer incidence was reported as 212.6 per 100.000 in Turkey (Ilter & Keskinkılıç, 2018). The increasing cancer incidence (Fitzmaurice et al, 2017) and discussions on PC have forced administrative and political decision-makers as well as researchers to find more cost-effective alternatives for treatment and care of cancer cases (Ciemins, Blum, Nunley, Lasher, & Newman, 2007;Dagovic et al, 2014;Dagovic, Zugic, & Jakovljevic, 2015;Jakovljevic, Malmose-Stapelfeldt, Milovanovic, Rancic, & Bokonjic, 2017;McGrath, Foote, Frith, & Hall, 2013;Radovanović, Dagović, & Jakovljević, 2011;Reid et al, 2018;Simoens et al, 2010;Smith, Brick, O'Hara, & Normand, 2014). Economic evidence in palliative care is important for making decisions regarding the allocation of resources and formulate/maintain accompanying relevant health policies (Jünger, Payne, Brearley, Ploenes, & Radbruch, 2012).…”

Dynamics of Health Care Financing and Spending in Serbia in the XXI Century

“…Since the beginning of the twenty-first century macroeconomic and political reforms, alongside with economy strengthening, led to rapid growth of health spending in Serbia (1). This trend has reached essentially a plateau level since the beginning of the global macroeconomic recession, recording fluctuations in 2008-2016 (2). These developments were led by several core-unfolding events across the nation.…”